Autologous Cells Derived Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies
Status:
Recruiting
Trial end date:
2024-04-07
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label, single-arm study to evaluate the primary safety and
efficacy of autologous anti-CD7 chimeric antigen receptor(CAR)-modified T cells(CAR7-Ts) in
patients with relapsed or refractory T lymphoid malignancies.